{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T14:29:23Z","timestamp":1652624963087},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/s00105-006-1218-4","type":"journal-article","created":{"date-parts":[[2006,9,8]],"date-time":"2006-09-08T03:06:37Z","timestamp":1157684797000},"page":"927-942","source":"Crossref","is-referenced-by-count":13,"title":["Raynaud-Ph\u00e4nomen in der Dermatologie"],"prefix":"10.1007","volume":"57","author":[{"given":"C.","family":"Sunderk\u00f6tter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1218_CR1","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.10191","volume":"46","author":"Andersen","year":"2002","unstructured":"Andersen GN, Mincheva-Nilsson L, Kazzam E et al. (2002) Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum 46: 1324\u20131332","journal-title":"Arthritis Rheum"},{"key":"1218_CR2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00105-003-0578-2","volume":"54","author":"Bali","year":"2003","unstructured":"Bali G, Aberer E (2003) Iloprost therapy in systemic sclerosis. Hautarzt 54: 845\u2013851","journal-title":"Hautarzt"},{"key":"1218_CR3","first-page":"137","volume":"47","author":"Bartolone","year":"1999","unstructured":"Bartolone S, Trifiletti A, De Nuzzo G et al. (1999) Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud\u2019s phenomenon. Minerva Cardioangiol 47: 137\u2013143","journal-title":"Minerva Cardioangiol"},{"key":"1218_CR4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.1780271009","volume":"27","author":"Beckett","year":"1984","unstructured":"Beckett VL, Conn DL, Fuster V et al. (1984) Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 27: 1137\u20131143","journal-title":"Arthritis Rheum"},{"key":"1218_CR5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/PL00011223","volume":"21","author":"Bettoni","year":"2002","unstructured":"Bettoni L, Geri A, Airo P et al. (2002) Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21: 244\u2013250","journal-title":"Clin Rheumatol"},{"key":"1218_CR6","first-page":"745","volume":"65","author":"Biasi","year":"1998","unstructured":"Biasi D, Carletto A, Caramaschi P et al. (1998) Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year. Rev Rhum Engl Ed 65: 745\u2013750","journal-title":"Rev Rhum Engl Ed"},{"key":"1218_CR7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.HYP.37.2.490","volume":"37","author":"Boffa","year":"2001","unstructured":"Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C (2001) Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 37: 490\u2013496","journal-title":"Hypertension"},{"key":"1218_CR8","first-page":"272","volume":"86","author":"Cattau","year":"1991","unstructured":"Cattau EL Jr, Castell DO, Johnson DA et al. (1991) Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 86: 272\u2013276","journal-title":"Am J Gastroenterol"},{"key":"1218_CR9","first-page":"381","volume":"15","author":"Ceru","year":"1997","unstructured":"Ceru S, Pancera P, Sansone S et al. (1997) Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis. Clin Exp Rheumatol 15: 381\u2013385","journal-title":"Clin Exp Rheumatol"},{"key":"1218_CR10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.1991.tb05565.x","volume":"31","author":"Challenor","year":"1991","unstructured":"Challenor VF, Waller DG, Hayward RA et al. (1991) Subjective and objective assessment of enalapril in primary Raynaud\u2019s phenomenon. Br J Clin Pharmacol 31: 477\u2013480","journal-title":"Br J Clin Pharmacol"},{"key":"1218_CR11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/01.CIR.72.3.466","volume":"72","author":"Coffman","year":"1985","unstructured":"Coffman JD, Rasmussen HM (1985) Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud\u2019s phenomenon. Circulation 72: 466\u2013470","journal-title":"Circulation"},{"key":"1218_CR12","doi-asserted-by":"crossref","unstructured":"Coleiro B, Marshall SE, Denton CP et al. (2001) Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40: 1038\u20131043","DOI":"10.1093\/rheumatology\/40.9.1038"},{"key":"1218_CR13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.freeradbiomed.2004.09.032","volume":"38","author":"Cracowski","year":"2005","unstructured":"Cracowski JL, Girolet S, Imbert B et al. (2005) Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. Free Radic Biol Med 38: 98\u2013103","journal-title":"Free Radic Biol Med"},{"key":"1218_CR14","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","volume":"46","author":"DeMarco","year":"2002","unstructured":"DeMarco PJ, Weisman MH, Seibold JR et al. (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46: 2983\u20132989","journal-title":"Arthritis Rheum"},{"key":"1218_CR15","first-page":"499","volume":"18","author":"Denton","year":"2000","unstructured":"Denton CP, Howell K, Stratton RJ, Black CM (2000) Long-term low molecular weight heparin therapy for severe Raynaud\u2019s phenomenon: a pilot study. Clin Exp Rheumatol 18: 499\u2013502","journal-title":"Clin Exp Rheumatol"},{"key":"1218_CR16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/rheumatology\/34.6.576","volume":"34","author":"Dolan","year":"1995","unstructured":"Dolan AL, Kassimos D, Gibson T, Kingsley GH (1995) Diltiazem induces remission of calcinosis in scleroderma. Br J Rheumatol 34: 576\u2013578","journal-title":"Br J Rheumatol"},{"key":"1218_CR17","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","volume":"42","author":"Dziadzio","year":"1999","unstructured":"Dziadzio M, Denton CP, Smith R et al. (1999) Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42: 2646\u20132655","journal-title":"Arthritis Rheum"},{"key":"1218_CR18","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","volume":"112","author":"Fries","year":"2005","unstructured":"Fries R, Shariat K, von Wilmowsky H, Bohm M (2005) Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy. Circulation 112: 2980\u20132985","journal-title":"Circulation"},{"key":"1218_CR19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/art.1780330218","volume":"33","author":"Fritzler","year":"1990","unstructured":"Fritzler MJ, Hart DA (1990) Prolonged improvement of Raynaud\u2019s phenomenon and scleroderma after recombinant tissue plasminogen activator therapy. Arthritis Rheum 33: 274\u2013276","journal-title":"Arthritis Rheum"},{"key":"1218_CR20","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"Galie","year":"2005","unstructured":"Galie N, Ghofrani HA, Torbicki A et al. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148\u20132157","journal-title":"N Engl J Med"},{"key":"1218_CR21","first-page":"786","volume":"28","author":"Gardinali","year":"2001","unstructured":"Gardinali M, Pozzi MR, Bernareggi M et al. (2001) Treatment of Raynaud\u2019s phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol 28: 786\u2013794","journal-title":"J Rheumatol"},{"key":"1218_CR22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/art.1780290822","volume":"29","author":"Goldberg","year":"1986","unstructured":"Goldberg J, Dlesk A (1986) Successful treatment of Raynaud\u2019s phenomenon with pentoxifylline. Arthritis Rheum 29: 1055\u20131056","journal-title":"Arthritis Rheum"},{"key":"1218_CR23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2177\/jsci.19.193","volume":"19","author":"Hiida","year":"1996","unstructured":"Hiida M, Ushiyama O, Suzuki N et al. (1996) The effect of beraprost sodium on the Raynaud\u2019s phenomenon. Nihon Rinsho Meneki Gakkai Kaishi 19: 193\u2013200","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"1218_CR24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0889-857X(03)00019-X","volume":"29","author":"Hummers","year":"2003","unstructured":"Hummers LK, Wigley FM (2003) Management of Raynaud\u2019s phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 29: 293\u2013313","journal-title":"Rheum Dis Clin North Am"},{"key":"1218_CR25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2710.1988.tb00171.x","volume":"13","author":"Janini","year":"1988","unstructured":"Janini SD, Scott DG, Coppock JS et al. (1988) Enalapril in Raynaud\u2019s phenomenon. J Clin Pharm Ther 13: 145\u2013150","journal-title":"J Clin Pharm Ther"},{"key":"1218_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2177\/jsci.18.29","volume":"18","author":"Kaburaki","year":"1995","unstructured":"Kaburaki J, Kuwana M, Akizuki M et al. (1995) Efficacy of beraprost sodium on Raynaud\u2019s phenomenon in patients with systemic sclerosis. Nihon Rinsho Meneki Gakkai Kaishi 18: 29\u201335","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"1218_CR27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard.44.1.30","volume":"44","author":"Kahan","year":"1985","unstructured":"Kahan A, Amor B, Menkes CJ (1985) A randomised double-blind trial of diltiazem in the treatment of Raynaud\u2019s phenomenon. Ann Rheum Dis 44: 30\u201333","journal-title":"Ann Rheum Dis"},{"key":"1218_CR28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/00005344-199410000-00016","volume":"24","author":"Kamphuis","year":"1994","unstructured":"Kamphuis J, Smits P, Thien T (1994) Vascular effects of pentoxifylline in humans. J Cardiovasc Pharmacol 24: 648\u2013654","journal-title":"J Cardiovasc Pharmacol"},{"key":"1218_CR29","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jbspin.2003.11.008","volume":"72","author":"Legendre","year":"2005","unstructured":"Legendre C, Allanore Y, Ferrand I, Kahan A (2005) Evaluation of depression and anxiety in patients with systemic sclerosis. Joint Bone Spine 72: 408\u2013411","journal-title":"Joint Bone Spine"},{"key":"1218_CR30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0889-857X(05)70295-7","volume":"22","author":"LeRoy","year":"1996","unstructured":"LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22: 675\u2013694","journal-title":"Rheum Dis Clin North Am"},{"key":"1218_CR31","first-page":"1782","volume":"30","author":"Matsuura","year":"2003","unstructured":"Matsuura E, Ohta A, Kanegae F et al. (2003) Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol 30: 1782\u20131787","journal-title":"J Rheumatol"},{"key":"1218_CR32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1526-4610.1992.hed3206298.x","volume":"32","author":"Mazagri","year":"1992","unstructured":"Mazagri R, Shuaib A (1992) Flunarizine is effective in prophylaxis of headache associated with scleroderma. Headache 32: 298\u2013299","journal-title":"Headache"},{"key":"1218_CR33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2133.1987.tb04122.x","volume":"117","author":"Meyrick","year":"1987","unstructured":"Meyrick Thomas RH, Rademaker M, Grimes SM et al. (1987) Nifedipine in the treatment of Raynaud\u2019s phenomenon in patients with systemic sclerosis. Br J Dermatol 117: 237\u2013241","journal-title":"Br J Dermatol"},{"key":"1218_CR34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.44.11.754","volume":"44","author":"Mohrland","year":"1985","unstructured":"Mohrland JS, Porter JM, Smith EA et al. (1985) A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud\u2019s syndrome. Ann Rheum Dis 44: 754\u2013760","journal-title":"Ann Rheum Dis"},{"key":"1218_CR35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1191\/1358863x02vm455oa","volume":"7","author":"Muir","year":"2002","unstructured":"Muir AH, Robb R, McLaren M et al. (2002) The use of Ginkgo biloba in Raynaud\u2019s disease: a double-blind placebo-controlled trial. Vasc Med 7: 265\u2013267","journal-title":"Vasc Med"},{"key":"1218_CR36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1165\/ajrcmb.18.5.2898","volume":"18","author":"Mutsaers","year":"1998","unstructured":"Mutsaers SE, Foster ML, Chambers RC et al. (1998) Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am J Respir Cell Mol Biol 18: 611\u2013619","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1218_CR37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0906-6705.2004.00208.x","volume":"13","author":"Namazi","year":"2004","unstructured":"Namazi MR (2004) Statins: novel additions to the dermatologic arsenal? Exp Dermatol 13: 337\u2013339","journal-title":"Exp Dermatol"},{"key":"1218_CR38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/000331978703800801","volume":"38","author":"Neirotti","year":"1987","unstructured":"Neirotti M, Longo F, Molaschi M et al. (1987) Functional vascular disorders: treatment with pentoxifylline. Angiology 38: 575\u2013580","journal-title":"Angiology"},{"key":"1218_CR39","first-page":"CD000953","volume":"Rev","author":"Pope","year":"2000","unstructured":"Pope J, Fenlon D, Thompson A et al. (2000) Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev: CD000953","journal-title":"Cochrane Database Syst"},{"key":"1218_CR40","first-page":"CD000954","volume":"Rev","author":"Pope","year":"2000","unstructured":"Pope J, Fenlon D, Thompson A et al. (2000) Ketanserin for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev: CD000954","journal-title":"Cochrane Database Syst"},{"key":"1218_CR41","first-page":"CD000956","volume":"Rev","author":"Pope","year":"2000","unstructured":"Pope J, Fenlon D, Thompson A et al. (2000) Prazosin for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev: CD000956","journal-title":"Cochrane Database Syst"},{"key":"1218_CR42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","volume":"298","author":"Rademaker","year":"1989","unstructured":"Rademaker M, Cooke ED, Almond NE et al. (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud\u2019s phenomenon in patients with systemic sclerosis: a double blind randomised study. Bmj 298: 561\u2013564","journal-title":"Bmj"},{"key":"1218_CR43","unstructured":"Rey RH, Marrero G, Chwojnik A et al. (1997) Effect of diltiazem on cold-induced left ventricular dysfunction in patients with systemic sclerosis. Medicina (B Aires) 57: 47\u201351"},{"key":"1218_CR44","first-page":"724","volume":"12","author":"Rhedda","year":"1985","unstructured":"Rhedda A, McCans J, Willan AR, Ford PM (1985) A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud\u2019s phenomenon. J Rheumatol 12: 724\u2013727","journal-title":"J Rheumatol"},{"key":"1218_CR45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00393-005-0692-x","volume":"64","author":"Riemekasten","year":"2005","unstructured":"Riemekasten G (2005) Recommendations of the German Society of Rheumatology on therapy of Raynaud syndrome and acral ulcerations. Z Rheumatol 64: 90\u201392","journal-title":"Z Rheumatol"},{"key":"1218_CR46","doi-asserted-by":"crossref","unstructured":"Riemekasten G, Sunderkotter C (2006) Vasoactive therapies in systemic sclerosis. Rheumatology (Oxford) (in press)","DOI":"10.1093\/rheumatology\/kel283"},{"key":"1218_CR47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s003930050070","volume":"57","author":"Riemekasten","year":"1998","unstructured":"Riemekasten G, Jepsen H, Burmester GR, Hiepe F (1998) Iloprost administration over 21 days as an effective therapy in systemic scleroderma--case report and review of the literature. Z Rheumatol 57: 118\u2013124","journal-title":"Z Rheumatol"},{"key":"1218_CR48","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896\u2013903","journal-title":"N Engl J Med"},{"key":"1218_CR49","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2133.1987.tb07356.x","volume":"117","author":"Rustin","year":"1987","unstructured":"Rustin MH, Almond NE, Beacham JA et al. (1987) The effect of captopril on cutaneous blood flow in patients with primary Raynaud\u2019s phenomenon. Br J Dermatol 117: 751\u2013758","journal-title":"Br J Dermatol"},{"key":"1218_CR50","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00558230","volume":"37","author":"Schmidt","year":"1989","unstructured":"Schmidt JF, Valentin N, Nielsen SL (1989) The clinical effect of felodipine and nifedipine in Raynaud\u2019s phenomenon. Eur J Clin Pharmacol 37: 191\u2013192","journal-title":"Eur J Clin Pharmacol"},{"key":"1218_CR51","first-page":"503","volume":"19","author":"Scorza","year":"2001","unstructured":"Scorza R, Caronni M, Mascagni B et al. (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud\u2019s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19: 503\u2013508","journal-title":"Clin Exp Rheumatol"},{"key":"1218_CR52","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","volume":"113","author":"Steen","year":"1990","unstructured":"Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113: 352\u2013357","journal-title":"Ann Intern Med"},{"key":"1218_CR53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI12020","volume":"108","author":"Stratton","year":"2001","unstructured":"Stratton R, Shiwen X, Martini G et al. (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108: 241\u2013250","journal-title":"J Clin Invest"},{"key":"1218_CR54","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00002281-199811000-00013","volume":"10","author":"Sturgill","year":"1998","unstructured":"Sturgill MG, Seibold JR (1998) Rational use of calcium-channel antagonists in Raynaud\u2019s phenomenon. Curr Opin Rheumatol 10: 584\u2013588","journal-title":"Curr Opin Rheumatol"},{"key":"1218_CR55","doi-asserted-by":"crossref","unstructured":"Sunderkotter C, Riemekasten G (2006) Das Raynaud Ph\u00e4nomen in der Dermatologie Teil 1: Pathophysiologie und Diagnostik. Hautarzt (in press)","DOI":"10.1007\/s00105-006-1192-x"},{"key":"1218_CR56","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","volume":"34","author":"Teh","year":"1995","unstructured":"Teh LS, Manning J, Moore T et al. (1995) Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud\u2019s phenomenon. Br J Rheumatol 34: 636\u2013641","journal-title":"Br J Rheumatol"},{"key":"1218_CR57","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","volume":"44","author":"Thompson","year":"2001","unstructured":"Thompson AE, Shea B, Welch V et al. (2001) Calcium-channel blockers for Raynaud\u2019s phenomenon in systemic sclerosis. Arthritis Rheum 44: 1841\u20131847","journal-title":"Arthritis Rheum"},{"key":"1218_CR58","first-page":"37","volume":"13","author":"Tosi","year":"1987","unstructured":"Tosi S, Marchesoni A, Messina K et al. (1987) Treatment of Raynaud\u2019s phenomenon with captopril. Drugs Exp Clin Res 13: 37\u201342","journal-title":"Drugs Exp Clin Res"},{"key":"1218_CR59","first-page":"71","volume":"18","author":"van","year":"1987","unstructured":"van der Meer J, Wouda AA, Kallenberg CG, Wesseling H (1987) A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud\u2019s phenomenon. Vasa Suppl 18: 71\u201375","journal-title":"Vasa Suppl"},{"key":"1218_CR60","first-page":"77","volume":"197","author":"Varela-Aguilar","year":"1997","unstructured":"Varela-Aguilar JM, Sanchez-Roman J, Talegon Melendez A, Castillo Palma MJ (1997) Comparative study of misoprostol and nifedipine in the treatment of Raynaud\u2019s phenomenon secondary to systemic diseases. Hemodynamic assessment with Doppler duplex. Rev Clin Esp 197: 77\u201383","journal-title":"Rev Clin Esp"},{"key":"1218_CR61","first-page":"2173","volume":"26","author":"Vayssairat","year":"1999","unstructured":"Vayssairat M (1999) Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 26: 2173\u20132178","journal-title":"J Rheumatol"},{"key":"1218_CR62","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","volume":"41","author":"Wigley","year":"1998","unstructured":"Wigley FM, Korn JH, Csuka ME et al. (1998) Oral iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 41: 670\u2013677","journal-title":"Arthritis Rheum"},{"key":"1218_CR63","first-page":"1407","volume":"19","author":"Wigley","year":"1992","unstructured":"Wigley FM, Seibold JR, Wise RA et al. (1992) Intravenous iloprost treatment of Raynaud\u2019s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19: 1407\u20131414","journal-title":"J Rheumatol"},{"key":"1218_CR64","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archderm.141.7.831","volume":"141","author":"Yung","year":"2005","unstructured":"Yung A, Reay N, Goodfield MD (2005) Improvement in digital flexibility and dexterity following ingestion of sildenafil citrate (viagra) in limited systemic sclerosis. Arch Dermatol 141: 831\u2013833","journal-title":"Arch Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1218-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-006-1218-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1218-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T23:37:12Z","timestamp":1558568232000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-006-1218-4"}},"subtitle":["Teil\u00a02: Therapie"],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1007\/s00105-006-1218-4","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}